<DOC>
	<DOCNO>NCT01803867</DOCNO>
	<brief_summary>This Phase I , multi-center , double-blind , randomize , placebo-controlled , dose-escalation study design evaluate safety , tolerability , pharmacokinetics , immunogenicity single intravenous ( IV ) administration rHIgM22 patient clinical presentation MS .</brief_summary>
	<brief_title>An Intravenous Infusion Study rHIgM22 Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Able give write informed consent , adequate cognitive function sign IRBapproved inform consent Meet diagnostic criterion MS , define revise ( 2010 ) McDonald criterion Man woman age 18 70 year , inclusive Women childbearing potential must negative serum pregnancy test Screening Visit Women childbearing potential engage heterosexual relation must agree practice adequate contraception least 60 day study dose . Women childbearing potential engage heterosexual relation practice adequate contraception must agree remain abstinent least 60 day study dose practice adequate contraception duration study Agree remain hospital 48 hour post infusion observation period , contact case emergency discharge Serum creatinine ≥1.5 mg/dL Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) alkaline phosphatase ≥1.5 time upper limit normal Angina , uncontrolled hypertension , clinically significant cardiac arrhythmia ( include atrial fibrillation ) , clinically significant cardiovascular abnormality clinically significant abnormal ECG Immunemediated disorder MS Investigator 's judgment , may affect interpretation result patient 's ability safely complete study Any clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , allergic anaphylactic reason , major disease ( MS ) , Investigator 's judgment , may affect interpretation result patient 's ability safely complete study . This include suicide attempt within past 1 year severe suicidal ideation within past 6 month patient opinion Investigator significant risk suicidal behavior MS relapse within 30 day prior screen treatment systemic ( oral , IV IM ) corticosteroid , except minimally absorbed topical inhalational preparation , within 30 day prior Screening Visit Initiation interferonbeta 1b ( Betaseron , extavia ) , interferon beta1a ( Avonex , Rebif ) , glatiramer acetate ( copaxone ) , natalizumab ( Tysabri ) , fingolimod ( Gilenya ) , dimethyl fumarate ( Tecfidera ® ) within 90 day prior Screening Visit , change dose regimen drug within 30 day prior Screening Visit . Initiation teriflunomide ( AUBAGIO® ) change dose regimen drug within 90 day prior Screening Visit . Treatment follow medication within 12 month prior Day 1 study : daclizumab , azathioprine , methotrexate , IV immunoglobulin , plasmaphoresis , mycophenolate mofetil ; discontinuation teriflunomide ( AUBAGIO® ) within 12 month prior Day 1 . History clinically significant infusion reaction administration biologics , include plasma exchange , intravenous immunoglobulin , monoclonal antibody natalizumab ( Tysabri ) Prior treatment total lymphoid irradiation , T cell Tcell receptor vaccination , alemtuzumab , mitoxantrone , cyclophosphamide , rituximab Received investigational agent therapy 30 day 4 pharmacokinetic halflives ( whichever longer ) prior Screening Visit plan enroll another investigational trial time study Contraindication brain MRI inability tolerate brain MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>MS</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>